Combinatorial therapy of chitosan hydrogel-based zinc oxide nanocomposite attenuates the virulence of *Streptococcus mutans*

Shima Afrasiabi¹, Abbas Bahador² and Alireza Partoazar³*

**Abstract**

**Background:** Biofilm formation is an important causative factor in the expansion of the carious lesions in the enamel. Hence, new approaches to efficient antibacterial agents are highly demanded. This study was conducted to evaluate the antimicrobial-biofilm activity of chitosan hydrogel (CS gel), zinc oxide/zeolite nanocomposite (ZnONC) either separately or combined together [ZnONC / CS gel (ZnONC-CS)] against *Streptococcus mutans* biofilm.

**Results:** MTT assay demonstrated that the ZnONC-CS exhibits a non-cytotoxic effect (> 90% cell viability) toward human gingival fibroblast cells at different dosages (78.1–625 μg/mL) within 72 h. In comparison with CS gel and ZnONC, ZnONC-CS was superior at biofilm formation and metabolic activity reduction by 33 and 45%, respectively; (*P* < 0.05). The field emission scanning electron microscopy micrographs of the biofilms grown on the enamel slabs were largely in concordance with the quantitative biofilm assay results. Consistent with the reducing effect of ZnONC-CS on biofilm formation, the expression levels of *gtfB*, *gtfC*, and *ftf* significantly decreased.

**Conclusions:** Taken together, excellent compatibility coupled with an enhanced antimicrobial effect against *S. mutans* biofilm has equipped ZnONC-CS as a promising candidate for dental biofilm control.

**Keywords:** Dental caries, *Streptococcus mutans*, Biofilms, Chitosan, Zinc oxide, Nanocomposites

**Introduction**

Dental caries is one of the multi-factorial diseases affecting people worldwide. Deep caries lesions can increase the risk of dental pulp infection. Carious lesions initiate where oral biofilms are allowed to grow and remain on the tooth surface [¹]. In general, the biofilm is a complicated matrix containing proteins and exopolysaccharides (EPS), providing a stable shelter for bacterial cells that is hard to remove [²]. Treatment of dental biofilms is a serious challenge due to their strong adhesion to the surface of teeth and tendency to calcify into dental calculus [³].

*Streptococcus mutans* is one of the primary microbial culprits of dental caries [⁴]. The cariogenic potential associated with *S. mutans* includes adhesion to tooth surfaces, synthesis of EPS via glucosyltransferases (Gtfs), stimulates biofilm formation, and the ability to use sucrose and generate an acidic environment [⁵]. The bacterium produces three Gtfs, –B, –C and –D, whose cooperative action is necessary for bacterial adhesion to the tooth surface [⁶]. GtfB and -C, which utilize the glucose moiety of sucrose as the substrate to produce extracellular glucosyl polymers, are encoded by the *gtfB* and -C genes, respectively [⁷]. *S. mutans* also produces a...
fructosyltransferase (Ftf), which synthesizes extracellular fructans from the fructose moiety of sucrose [8]. They can act as binding sites for bacterial aggregations [9]. The bacterial composition of dental biofilms is mainly formed in areas that are protected from the forces on dental biofilms reduction by the tongue, cheeks, and tooth brushing [10]. Mechanical approaches and antimicrobial agents for controlling dental biofilms are limited by adverse effects such as damage of oral mucosa, dysgeusia, burning sensation, ulcerative lesions, and enamel erosion and therefore, are not suitable for long-term usage [1, 2]. Fluoride is a well-known antiplaque agent via the demineralization/ remineralization process. However, an adverse effect like fluorosis may occur if the fluoride excessive use [11]. Therefore, early intervention with minimal side effects should be considered to control the dental biofilm formation.

Despite the novel function of nanoparticles (NPs) that have been acted rather than their bulk materials, the aggregation of NPs usually is an unavoidable problem [12, 13]. Nanocomposites (NCs) have been employed as versatile tolls to control the major limitations in growing NPs size and stabilization [14]. Zinc oxide nanomaterials are recognized to be Generally Regarded As Safe (GRAS) by the Food and Drug Administration (FDA) [15] which have several advantages such as safety as well as anti-biofilm and antimicrobial activities in a broad spectrum of microorganisms. Small size and increased surface/volume ratio of NPs permit them to penetrate or interact with bacterial membranes, resulting in cell membrane destruction, leakage of intracellular contents, and finally bacterial death [16, 17].

Zeolite (Ze) is a microporous crystalline material of aluminosilicate, which can slowly release pre-loaded antimicrobials over long periods [17, 18]. Zinc oxide NPs (ZnO-NPs) doped Ze (ZnONC) showed a wide range of antibacterial properties against Gram-positive and Gram-negative bacteria [14, 17]. Moreover, chitosan (CS) is a natural linear polycationic biopolymer with good biocompatibility, biodegradability, low toxicity, and antibacterial activity that has adhesion properties to mucosal surfaces [19]. Bioadhesive characteristics of CS would prolong its contact time with the treatment site and further availability of the release content [20].

The CS hydrogel (CS gel) form causes its long-term storage and more application in different formulations [21]. According to the ability of free amino groups in the CS compound that perfectly complexes with metals and metal oxide NPs, there is a novel strategy to use the combination polymers with other nanosized metal oxides such as ZnO NPs as the antimicrobial agent [22, 23]. However, there is no any information about the beneficial effects of CS gel in combination with ZnONC (ZnONC-CS) on S. mutans to obtain a synergistic effect for better antibacterial activity so far. In that sense, this study aimed to combine the CS gel with ZnONC to attenuate S. mutans virulence properties as well as their effect on the biocompatibility in vitro.

**Results**

**MICs of CS gel, ZnONC, and ZnONC-CS**

ZnONC, ZnONC-CS (both at 78.1–1250 μg/mL) and CS gel (156.2–2500 μg/mL) significantly inhibited S. mutans growth when compared to control (P < 0.05). Lower concentrations of ZnONC and ZnONC-CS (both at 2.4–39 μg/mL) and CS gel (4.8–78.1 μg/mL), also affected S. mutans growth, but this was not statistically significant (P > 0.05). Therefore, the MIC of ZnONC, ZnONC-CS and CS gel was 78.1, 78.1 and 156.2 μg/mL, respectively.

**In vitro cytotoxicity assay of CS gel, ZnONC, and ZnONC-CS**

The cytotoxic effects of CS gel, ZnONC, and ZnONC-CS were evaluated with HGFs in vitro. The cell viability was measured for extraction media of materials mentioned above with different concentrations (concentration is shown in Fig. 1) up to 72 h. According to the results, the CS gel toxicity is increased upon increasing the concentration of CS gel (more than 156.2 μg/mL) and incubation up to 48 h didn’t show any significant effect on cell viability. As it can be seen in Fig. 1, the cell viability did not change significantly in the low concentrations of ZnONC up to 78.1 μg/mL (at all times; P > 0.05) while the cell viability was decreased (P < 0.05) with increasing concentration (156.2–625 μg/mL) and/or exposure time (48 and 72 h) of the nanocomposite. As seen in Fig. 1, the ZnONC-CS did not change the cell viability upon changing the incubation time which shows the biocompatibility of ZnONC-CS. The ZnONC-CS treated cells decreased the cytotoxicity compared to ZnONC under similar conditions. The viability was determined greater than 90% up to the concentration of 625 μg/mL of ZnONC-CS at all time points (P > 0.05). The permissible limit of cyto compatibility is considered to be > 75%, according to ISO standards 10,993–5:2009. Therefore, ZnONC-CS can be considered a safe product in this stage.

**Effects of CS gel, ZnONC, and ZnONC on S. mutans biofilm formation ability inhibition**

The results of this study demonstrated that 39 μg/mL (½ MIC) of ZnONC-CS decreased 33% of biofilm formation of S. mutans (P = 0.00). In contrast, Biofilm formation of S. mutans was not significantly reduced with 78.1 and 39 μg/mL (both at ½ MIC) of CS gel and ZnONC (3.15 and 14.23%, P = 0.91 and 0.07, respectively). Besides, the statistical analyses...
indicated a significant difference between the ZnONC-CS group and other treatment groups (CS gel and ZnONC), \( P = 0.00 \) and 0.02, respectively, however, no differences were found between the CS gel group and ZnONC group \( (P = 0.18) \). These results provide evidence that the ZnONC-CS can significantly affect the biofilm formation of \( S. \) mutans (Table 1).

Assessment of metabolic activity

As shown in Table 1, the metabolic activity of \( S. \) mutans after treatment with CS gel, ZnONC, and ZnONC-CS at sub-MIC concentration was decreased up to 19.75, 30, and 45%, respectively. These results show that ZnONC-CS can significantly affect the metabolic activity of \( S. \) mutans \( (P = 0.00) \). The data suggest that the ZnONC and CS gel at sub-MIC concentration does not significantly inhibit the biofilm formation, but metabolic activity is affected.

Fe-SEM of biofilm formation ability inhibition

In the present work, a study was performed to visualize the effect of CS gel, ZnONC and ZnONC-CS on the architecture of the \( S. \) mutans in the biofilm. For this purpose, the cell structure of treated and untreated cells was investigated using Fe-SEM, and the results presented are in Fig. 2. The untreated bacterial cells of \( S. \) mutans demonstrated that cells with large clusters embedded in an EPS (Fig. 2a). When biofilm was treated with a sub-MIC concentration of CS gel and ZnONC, the numbers of bacteria were reduced but not very impressive (Fig. 2b, c). A more substantial decrease in the number of cells and single cells or short chains was observed when the biofilm was treated with ZnONC-CS (Fig. 2d).

gtfB, \(-C\), and \(f\)tf gene expression reduction by ZnONC-CS

The antibacterial activities of CS gel, ZnONC, and ZnONC-CS against \( S. \) mutans were further confirmed by quantitative Real-Time PCR (Fig. 3). After treatment of \( S. \) mutans with different experimental groups, the profile of gene expression was determined. As the results reveal, the \(g\)tf\(B\), \(-C\), and \(f\)tf gene expression profiling downregulated in \( S. \) mutans cells 1.0, 1.02, 1.81- and 1.73, 1.84, 1.49-fold following CS gel and ZnONC, respectively. The expression level of \(g\)tf\(B\), \(-C\), and \(f\)tf
reduced 4.16, 4.40, and 2.88-fold in ZnONC-CS. Based on the results, the level of gene expression in ZnONC-CS compared to control was remarkably different ($P < 0.05$), while no significant differences were found in the expression of mentioned genes following CS gel and ZnONC groups ($P > 0.05$).

**Discussion**
The bacterial biofilms associated with infected dental caries are a global public health problem [24]. The bacteria embedded in biofilms display a set of ‘emergent properties’ that differ noticeably from the planktonic lifestyle [25]. Dental caries is a consequence of oral microbial dysbiosis. Although several therapeutic strategies including, antimicrobial peptides, probiotics, bacteriophages have produced encouraging effects to reverse dysbiosis, the development of new and effective strategies is an urgent need to control biofilm expansion [24, 26].

Metal oxide NPs such as ZnO-NPs are reported to induce reactive oxygen species (ROS) and the cells exposed to oxidative stress which damage cellular components [27]. In a previous study, it has been revealed that the ZnO-NPs modification with polymeric materials reduces their cytotoxicity. Furthermore, CS can mask the NPs and subsequently, preventing the release of Zn$^{2+}$ ions and ROS [28]. Our findings showed that ZnONC-CS has a stronger antibacterial effect along with lower cytotoxicity compared to CS gel or ZnONC. It suggests that CS plays
an important role in the enhancement of antibacterial activity against S. mutans and reduction of cell cytotoxicity on HGFs cells. In accordance with the evidences extracted of this study, Mehta et al. have reported that combination of CS with ZnO nanomicelles (CZNPs) shows to be more effective against multiple drug resistance (MDR) Gram-positive biofilms than CS or ZnO alone. Moreover, CZNPs have been established as relatively non-toxic compared to both ZnO and CS NPs alone [29].

In the current study, CS gel and ZnONC at their sub-MIC concentration had slightly anti-biofilm activity on S. mutans (with an inhibition rate of 3.15 and 14.23%, respectively). In our previous study, anti-biofilm trait of ZnONC against Enterococcus faecalis 

- C, and ftf gene than that of CS gel or ZnONC alone. This result was in accordance with Badawy et al., who reported that prepared CS/ZnONC causes a significant decrease in biofilm formation of Pseudomonas aeruginosa. Also, CS/ZnONC causes more decrease in the expression of LasI and RhlI genes of P. aeruginosa than exposure to the CS alone [31]. Based on the results presented here, it is obvious that the antibacterial activity of ZnONC-CS is greater than that of CS or ZnONC alone. Therefore, ZnONC-CS could be potential therapeutic agents for attenuating the gtfB, −C, and ftf activity known virulence attributes of S. mutans. Moreover, the current results of this study showed that gtfC was affected in the presence of ZnONC-CS more than the other examined genes. Highly homologous gtfB, and -C gene, resulting in an impressive decrease in the generation of water-insoluble glucans [32].

Overall, the results of the present study showed that ZnONC-CS has a reinforcing effect on cariogenic virulence factors of S. mutans along with lower cytotoxicity compared to other groups. Also, the antimicrobial effects of ZnONC-CS should be assessed on multispecies dental biofilms and further studies are needed for the full understanding of the performance and safety of this formulation in vivo studies. Therefore, concerning limitation of this study, new investigations need to verify the clinical relevance of these results. Finally, Our findings suggest that ZnONC-CS could potentially use as an anti-biofilm agent in mouth rinse formulations and oral healthcare products.

Conclusion
Our findings revealed that the inhibitory effect of ZnONC-CS accelerates reduction of the biofilm formation and cariogenic properties of S. mutans rather than ZnONC or CS alone. The biocompatibility of ZnONC-CS in vitro assessment was improved using its effective concentration that suggests the clinical prospects of this nanohydrogel in the control of dental biofilms.

Methods
Preparation of ZnONC
ZnONC was synthesized and characterized in our previous study [17]. Briefly, zeolite powder was shacked in a round bottom flask containing deionized water (D.W) for 1 h, and filtered before being dried at 80 °C. The Zn^2+ exchanged zeolites were performed by impregnation of 10 g of zeolite powder into 7 g of a Zn (acetate) 2. 2 H2O aqueous solution under stirring conditions at 60 °C for 1 h. For fabrication of ZnO nanoparticle on the zeolite bed, a solution of NaOH 1 M was added to the suspension to obtain pH = 12. After 2 h, the composite materials were collected by filtration and was washed thoroughly with D. W to remove the excess zinc, and dried in the oven at 80 °C. Then the product was calcined for 2 h at 400°C. The ZnONC was analyzed by x-ray diffraction, x-ray fluorescence and field emission scanning electron microscopy (Fe-SEM) coupled with energy dispersive x-ray. The results revealed that the morphology of the ZnONC is spherical with an average size of 30 nm [17].

Preparation of CS solution
A CS (Sigma, USA) stock solution (1 g/ 100 mL) was prepared in 1% (v/v) acetic acid and the mixture solution was subjected to constant stirring with a magnetic stirrer at ambient temperature overnight. Then, the CS solution was sterilized in an autoclave (121 °C, 15 min) [33].

Preparation of ZnONC-CS
Five mL of CS solution was mixed with 5 mg of ZnONC for 60 min at 37°C using a magnetic stirrer. The resultant light-yellow viscous solution turns into white precipitate with slow addition of NaOH (1 M) until the pH reached 8.0–8.5. The final product was kept at 4°C to settle down for 24 h. Similarly, a blank CS hydrogel...
was prepared as mentioned above without the ZnONC content.

**Bacterial strain and culture conditions**

*S. mutans* ATCC 35668 was obtained from the Iranian Biological Resource Center (Tehran, Iran) and grown in brain–heart infusion broth (BHI; Laboratorios Conda, Torrejón de Ardoz, Spain) aerobically (5% CO₂) at 37 °C for 24 h.

**Cytotoxicity assessment**

Human gingival fibroblasts (HGFs; IBRC C10459) purchased from the Iranian Biological Resource Center (Tehran, Iran) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Biowest, France) supplemented with 10% fetal bovine serum (Gibco, UK) and pen-streptomycin (Biowest, France). The cells were seeded into the 96-well microtiter plate at a density of 10,000 cells/well followed by overnight incubation. Parallel to this experiment, a range of concentrations from 78.1 to 625 μg/mL was added to each dilution and incubated at 5% CO₂ for 48 h at 37 °C in 5% CO₂ to allow for biofilm formation. After incubation, the microplate contents were emptied out from each well and washed three times with PBS to remove the unadhered bacteria. The cells in the biofilm were stained for 15 min with 0.1% crystal violet (0.1%, w/v). After washing thrice with PBS, the bound dye was eluted with 150 μL of 95% ethanol under mild shaking, and absorbance at 550 nm was determined using a microplate reader (Thermo Fisher Scientific, US).

**Determination of the minimum inhibitory concentrations (MICs)**

The MIC of the ZnONC, CS gel, and ZnONC-CS against *S. mutans* was determined by the microdilution method as recommended by the Clinical and Laboratory Standards Institute guidelines [36]. Briefly, 100 μL of BHI broth was added to the well of a round-bottom 96-well microtiter plate, and 100 μL of ZnONC, CS gel, and ZnONC-CS (all stock solution = 5 mg/mL) was then added to the first well in column 1, 2, and 3, respectively. They were diluted to 1:2. Afterward, 100 μL of *S. mutans* suspension (1.5 × 10⁵ CFU/mL) was added to each dilution and incubated at 37 °C for 24 h in 5% CO₂. Following incubation, the contents of each well were serially diluted and plated onto BHI agar plates (Merck, Darmstadt, Germany) and incubated for 48 h at 37 °C in 5% CO₂. Subsequently, the CFU/mL was calculated using the method of Breed et al. [37]. MIC was interpreted as the lowest level concentration of the products at which bacterial growth was inhibited. Sub-MIC values were one dilution lower than MIC values and were applied for evaluation of their ability to abolish *S. mutans* virulence activity.

**Biofilm formation evaluation by crystal violet**

Quantification of the biofilm formation ability of *S. mutans* was performed according to a previous study [38]. Briefly, 200 μL aliquots of *S. mutans* cells suspended in planktonic cultures at a final concentration of 1.5 × 10⁵ CFU/mL were transferred to flat-bottomed 96-well microtiter plate. Bacterial cells were treated with ZnONC, CS gel, and ZnONC-CS at sub-MIC level, and the plate was incubated for 48 h at 37 °C in 5% CO₂ to allow for biofilm formation. After incubation, the microplate contents were emptied out from each well and washed three times with PBS to remove the unadhered bacteria. The cells in the biofilm were stained for 15 min with 200 μL of crystal violet (0.1%, w/v). After washing thrice with PBS, the bound dye was eluted with 150 μL of 95% ethanol under mild shaking, and absorbance at 550 nm was determined using a microplate reader (Thermo Fisher Scientific, US).

**XTT-reduction assay**

The metabolic activity of treated cells with CS gel, ZnONC, and ZnONC-CS was determined by the reduction of sodium 3-[1-(phenylamino-carbonyl)-3, 4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate (Roche Applied Science, Indianapolis, IN, US), as previously described [39]. One hundred microliters of culture (1.5 × 10⁵ cells/mL) was dispensed in 96-well microtiter plate supplemented with sub-MICs of CS gel, ZnONC, and ZnONC-CS until 24 h at 37 °C. Afterward, the prepared solution of the XTT solution (50 μL) was added to each well and mixed thoroughly. The plate was incubated in the dark at 37 °C for 3 h. The reduced formazan-colored was spectrophotometrically measured using a microplate reader (492 nm).

**Fe-SEM imaging**

To mimic the biofilm environment, an ex vivo study was performed to investigate the effect of ZnONC, CS gel, and ZnONC-CS on the structure of 48 h grown biofilms on human enamel slab (3 mm × 3 mm × 1 mm). Saliva was collected from a healthy volunteer and then centrifuged at 8000 g for 15 min at 4 °C. Each enamel slab was placed in 200 μL of the sterilized saliva of a 24-well microtiter plate. The plate was then incubated at 37 °C for 2 h to coat the human enamel slabs with a salivary pellicle. Post incubation, the human enamel slabs were carefully washed with PBS. Saliva-coated enamel slabs were suspended into the 96-well microtiter plate containing 200 μL of *S. mutans* suspension (1.5 × 10⁵ CFU/mL) treated with CS gel, ZnONC, and ZnONC-CS at sub-MIC concentration. Saliva-coated enamel slabs treated with BHI broth used as
the control. The biofilm was grown on these saliva-coated human enamel slabs for 48 h. At the end of this incubation period, the medium was discarded, and the biofilms were fixed using methanol and then dehydrated in increasing concentrations of ethanol (20, 40, 60, 80, and 100%). The human enamel slabs were finally dried, then mounted, and sputter-coated with a thin layer of gold-palladium and then investigated by Fe-SEM (HITACHI S-4160, Japan).

### gtfB, gtfC, and ftf gene expression under the planktonic condition

In the current study, the changes of gtfB, gtfC, and ftf gene expression of *S. mutans* were analyzed in different treatment groups according to the study design. Briefly, the *S. mutans* ATCC 35668 strain grown in BHI broth in presence of CS gel, ZnONC, or ZnONC-CS. An untreated sample was used as the control. Subsequently, the total RNA was extracted at the middle of the exponential phase of growth (Treatment duration - 6 h; PH: 6.5) using the RNX-plus solution (SinaClon, Iran) according to the manufacturer’s instructions. Traces of genomic DNA were removed using the RNase-free DNase I treatment (Thermo Scientific GmbH, Deutschland, Germany). The amount and quality of extracted RNA were based on the 260/280-nm ratio measured using a NanoDrop (Thermo Fisher Scientific, US). cDNA synthesis was performed by RevertAid First Strand cDNA Synthesis Kit (Fermentas), according to the manufacturer’s instructions. Quantitative real-time PCR (qRT-PCR) was performed with a Line-GeneK Real-Time PCR Detection System (Bioer Technology, Hangzhou, China). A sequence of primers used in this research: gtfB F: 5’-TGGTTGTACT GTCAAATGAAGA-3’; gtfB R: 5’-GCTACTGATTGTGCG TTACTG-3’; gtfC F: 5’-GAGTTGGATCGTCTAAGT-3’; gtfC R: 5’-CTGGTTGCTGTATTGTATGTT-3’; ftf F: 5’-ACGGCGACTTCTCTATAT-3’; ftf R: 5’-TTACTG CGGACTTCTATAC-3’; 16S rRNA F: 5’-GCAGAAGGGG AGATGGAAT-3’; 16S rRNA R: 5’-GGCCTAACAC CTAGCAACTCA-3’ [40]. The mRNA levels were quantified in relation to endogenous control gene coding for *16S rRNA*. Changes in expression levels of target genes were analyzed using the Eq. 2$^{\Delta\Delta Ct}$ [41].

### Statistical analysis

All these experiments were done at least three times and the values are expressed as mean ± standard deviation. The commercial software SPSS version 26 was used for statistical analyses.

Statistical analysis was performed using the independent-samples *t*-test to compare two groups. Differences among more than two groups were analyzed by one-way ANOVA followed by the Tukey HSD post hoc test, with the significance level set at 0.05.

### Acknowledgements

Not applicable.

### Authors’ contributions

Sh: A conducted all laboratory work and performed data collation, analysis and manuscript writing. A. P revised the manuscript. All authors involved in the design of the study and confirmed the final version before submission.

### Funding

This work was funded by Tehran University of Medical Sciences & Health Services, grant No: 99-2-209-45066. The funding body had no role in the design of the study, collection, analysis, or interpretation of data, or writing of the manuscript.

### Availability of data and materials

All documents and additional data are available from the corresponding author upon reasonable request.

### Ethics approval and consent to participate

The study was approved by the Ethics Committee of Tehran University of Medical Sciences (IR.TUMS.MEDICINE.REC.1399.663). Written informed consent was obtained from all participants in this study. All experiments presented were performed in accordance with relevant protocols approved by the Tehran University of Medical Sciences (Protocol approval: No: 99-2-209-45066).

### Consent for publication

Not applicable.

### Competing interests

The authors declare no conflicts of interest.

### Author details

1. Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 2. Oral Microbiology Laboratory, Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 3. Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Received: 20 October 2020 Accepted: 11 February 2021

Published online: 24 February 2021

### References

1. Gholibegloo E, Karbasi A, Pourhajibagher M, Chiniforush N, Ramazani A, Albari T, et al. Carnosine-graphene oxide conjugates decorated with hydroxyapatite as promising nanocarrier for ICG loading with enhanced antibacterial effects in photodynamic therapy against Streptococcus mutans. J Photochem Photobiol B. 2018;181:1–7.

2. Ashrafi B, Rashidpour M, Marzban A, Soroursh S, Azadpour M, Delfani S, et al. Mentha piperita essential oils loaded in a chitosan nanogel with inhibitory effect on biofilm formation against *S. mutans* on the dental surface. Carbohydr Polym. 2019;212:142–9.

3. Ostadhossein F, Misra SK, Tripathi I, Kravchuk V, Vulugundam G, LoBato D, et al. Dual purpose hafnium oxide nanoparticles offer imaging and antibiotic effects in photodynamic therapy against Streptococcus mutans. J Photochem Photobiol B. 2018;181:1–7.

4. Lemos JA, Palmer SR, Zeng L, Wen ZT, Kajfasz JK, Freires IA, et al. The biology of Streptococcus mutans. Microbiol Spectr. 2019;7(1). doi: 10.1128/microbiolspec.GPP3-0051-2018.

5. Senadheera MD, Guggenheim B, Spatafora GA, Huang Y-CC, Choi J, Hung DC, et al. A VicRK signal transduction system in Streptococcus mutans affects gtfBCD, gfpB, and ftf expression, biofilm formation, and genetic competence development. J Bacteriol. 2005;187(12):4064–76.

6. Fujitani T, Hoshino T, Ooshima T, Hamada S. Differential and quantitative analyses of mRNA expression of glucosyltransferases from Streptococcus mutans MT8148. J Dent Res. 2002;81(2):126–35.

7. Ren Z, Cui T, Zeng J, Chen L, Zhang W, Xu X, et al. Molecule targeting glucosyltransferase inhibits Streptococcus mutans biofilm formation and virulence. Antimicrob Agents Chemother. 2016;60(1):26–35.
8. Lee SF, Delaney GD, Ellikateeb M. A two-component coRS regulatory system regulates expression of fructosyltransferase and a novel extracellular carbohydrate in Streptococcus mutans. Infect Immun. 2004;72(7):7396–73.
9. Shemesh M, Tarn A, Feldman M, Steinberg D. Differential expression profiles of Streptococcus mutans ftf, gtf and vicR genes in the presence of dietary carbohydrates at early and late exponential growth phases. Carbohydr Res. 2006;341(12):2090–7.
10. Metwalli KH, Khan SA, Krom BP, Jabri-Rask MA. Streptococcus mutans, Candida albicans, and the human mouth: a sticky situation. PLoS Pathog. 2013;9(10):e1003616.
11. Li J, Wu T, Peng W, Zhu Y. Effects of resveratrol on cariogenic virulence properties of Streptococcus mutans. BMC Microbiol. 2020;20(1):11–11.
12. Rao C, Das A, Bank S, Singh B. ZnO/Curcumin nanocomposites for enhanced inhibition of Pseudomonas aeruginosa virulence via LasR-RhlR quorum sensing systems. Mol Pharm. 2019;16(8):3399–413.
13. Cheng X-W, Meng QY, Chen JY, Long YC. A facile route to synthesize mesoporous ZSM-5 zeolite incorporating high ZnO loading in mesopores. Microporous Mesoporous Mater. 2012;153:198–203.
14. Alswat AA, Ahmad MB, Saleh TA, Hussein MZB, Ibrahim NA. Effect of zinc oxide amounts on the properties and antibacterial activities of zeolite/zinc oxide nanocomposite. Mater Sci Eng C Mater Biol Appl. 2016;68:S505–11.
15. Noshirvani N, Ghanbarzadeh B, Mokarram RR, Hashemi M. Novel active packaging based on carboxymethyl cellulose-chitosan-ZnO NPs nanocomposite for increasing the shelf life of bread. Food Packag Shelf Life. 2017;11:106–14.
16. Amirnejad S, Emaminia S, Davoudian SH, Pourmohammad S, Hamishehkar H, Roufegarinejad L. Preparation and characterization of gelatin-based nanocomposite containing chitosan nanofiber and ZnO nanoparticles. Carbohydr Polym. 2019;216:376–84.
17. Paroazar A, Talaee N, Bahador A, Pourhajibagher M, Dehpour S, Sadati M, et al. Antifungal activity of natural zeolite supported NanoZnO: inhibition of Esp gene expression of enterococcus faecalis. Nanomedicine (Lond). 2019;14(6):675–87.
18. Malic S, Rai S, Redfem J, Pritchett J, Liao W, Veran J, et al. Zeolite-embedded silver extends the activity of antibiotic dental acrylics. Colloids Surf B Biointerfaces. 2019;173:52–7.
19. Tsai T, Chien H-F, Wang T-H, Huang C-T, Ker Y-B, Chen C-T. Chitosan augments photodynamic inactivation of gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2011;55(1):889–90.
20. Chen CP, Hsieh C-M, Tsai T, Yang J-C, Chen C-T. Optimization and evaluation of a chitosan/hydroxypropyl methylcellulose hydrogel containing toludine blue O for antimicrobial photodynamic inactivation. Int J Mol Sci. 2015;16(9):20859–72.
21. Furuki T, Komoto D, Hashimoto H, Tamura H. Preparation of chitosan hydrogel and its solubility in organic acids. Int J Biol Macromol. 2017;104:1620–5.
22. Mohammed AN, Aziz SAAA. The prevalence of Campylobacter species in broiler flocks and their environment: assessing the efficiency of chitosan/zinc oxide nanocomposite for adopting control strategy. Environ Sci Pollut Res Int. 2019;26(29):30777–87.
23. Hu X, Jia X, Zhi C, Jin Z, Miao M. Improving the properties of starch-based antimicrobial composite films using ZnO-chitosan nanoparticles. Carbohydr Polym. 2019;210:204–9.
24. Ribeiro SM, Fratucelli ED, Bueno PC, de Castro MKV, Francisco AA, Cavaleiro AJ, et al. Antimicrobial and antifungal activities of Casearia sylvestris extracts from distinct Brazilian biomes against Streptococcus mutans and Candida albicans. BMC Complement Altern Med. 2019;19(1):308.
25. Flemming H-C, Edlund A. Exploiting the oral microbiome to prevent tooth decay: has evolution already provided the best tools? Front Microbiol. 2019;9:3323.
26. Siddiqi KS, ur Rahman A, Husen A. Properties of zinc oxide nanoparticles and their activity against microbes. Nanoscale Res Lett. 2018;13(1):141.
27. Ghaffari H, Tavakoli A, Noradi A, Tabaraei A, Bokhari-Salim F, Zahiratnashtesh M, et al. Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine. J Biomed Sci. 2019;26(1):70.
28. Mekha M, Allen-Gipsen D, Mohapatra S, Kindy M, Limayem A. Study on the therapeutic index and synergistic effect of Chitosan-zinc oxide nanomicellar composites for drug-resistant bacterial biofilm inhibition. Int J Pharm. 2019;565:472–80.
29. Yusof NAA, Zain NM, Paull N. Synthesis of ZnO nanoparticles with chitosan as stabilizing agent and their antibacterial properties against Gram-positive and Gram-negative bacteria. Int J Biol Macromol. 2019;124:1312–6.
30. Badawy MSE, Riaad OKM, Tahir F, Zaki SA. Chitosan and chitosan-zinc oxide nanocomposite inhibit expression of Las and Rhl genes and quorum sensing dependent virulence factors of Pseudomonas aeruginosa. Int J Biol Macromol. 2020;149:1109–17.
31. Wen ZT, Yates D, Ahn S-J, Burne RA. Biofilm formation and virulence expression by Streptococcus mutans are altered when grown in dual-species model. BMC Microbiol. 2010;10(1):111.
32. Tantala J, Thumanu K, Rachtanapun C. An assessment of antibacterial mode of action of chitosan on Listeria innocua cells using real-time HATR-FTIR spectroscopy. Int J Biol Macromol. 2019;135:386–93.
33. Roy A, Joshi M, Butola B, Ghosh S. Evaluation of biological and cytocompatible properties in nano silver-clay based polyethylene nanocomposites. J Hazard Mater. 2020;384:121309.
34. International Organization for Standardization. “UNI EN ISO 10993-5: 2009” in Biological evaluation of medical devices– part 5: in vitro cytotoxicity testing. Geneva: International Organization for Standardization; 2009.
35. CLSI C. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. M100-S24 January, 2014.
36. Breed RS, Dotterrer W. The number of colonies allowable on satisfactory agar plates. J Bacterial. 1916(1):321.
37. Borges S, Silva J, Teixeira P. Survival and biofilm formation by group B streptococci in simulated vaginal fluid at different pHs. Antonie Van Leeuwenhoek. 2012;101(3):677–82.
38. Gahlavat G, Shikha S, Chaddha BS, Choudhry SR, Mayilraj S, Choudhry AR. Microbial glycolipoprotein-capped silver nanoparticles as emerging antibacterial agents against cholora. Microb Cell Factories. 2016;15(1):25.
39. Afrasiabi S, Pourhajibagher M, Chiniforouh N, Bahador A, Propolis nanoparticle enhances the potency of antimicrobial photodynamic therapy against Streptococcus mutans in a synergistic manner. Sci Rep. 2020;10(1):1–16.
40. Litvak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.